Author argues Liquidia's Yutrepia is taking share from JNJ's Uptravi and UTHR's Tyvaso, making the $3B market cap cheap relative to projected revenue.
LQDA — LONG Author argues Liquidia's Yutrepia is eating into JNJ's Uptravi and UTHR's Tyvaso, which together represent a ~$3.62B TAM. Yutrepia is claimed to be superior in side effects and usability, and with 2,200 patients generating $148M in H2 2025 (ARPP ~$140k), the author projects Q1 2026 revenue of at least $110M+ and ~6,750 patients (30% market share) by mid-2027, implying $900M+ annual revenue. At a $3B market cap, the author calls the stock a steal. No specific risk is stated.
$LQDA DeepDive. $3B marketcap looks incredibly cheap..
This Reddit post, published January 14, 2026, features u/investak discussing LQDA. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/investak · Tickers: LQDA